Eiken Chemical

4549.TTSE PRIMEPharmaceutical

Key numbers · FY ended 2026-03

Revenue¥41.9bn+3.4% YoY Operating income¥2.9bn-2.7% YoY Net income (owners)¥3.7bn+66.4% YoY Total assets¥62.7bn+0.5% YoY EPS (basic)¥112.52+73.6% YoY

Full financial history and reports →

Stock price4549 · View chart ↗

Open the price chart on TradingView.

Latest filings

Fri, Jul 24 · JST1 filing

15:345% STAKEEiken Chemical · Dalton Investments, Inc. + 2 joint holders · 32.84% → 31.01%−1.83pp

Tue, Jun 30 · JST1 filing

15:315% STAKEEiken Chemical · Dalton Investments, Inc. + 2 joint holders · 32.84% → 32.84%

Fri, Jun 19 · JST1 filing

15:375% STAKEEiken Chemical · Dalton Investments, Inc. + 2 joint holders · 32.84% → 32.84%

Fri, Jun 12 · JST1 filing

10:10MATERIALEiken Chemical · Change of representative director

Wed, Apr 8 · JST1 filing

15:355% STAKEEiken Chemical · Dalton Investments, Inc. + 2 joint holders · 32.79% → 32.84%+0.05pp

All filings →

Major holders (5%+) · 3

Holder	Stake	Change	Filed
Dalton Investments, Inc.	17.92%	-1.83pp	2026-07-24
NIPPON ACTIVE VALUE FUND PLC	9.46%	0.00pp	2026-07-24
Asset Value Investors Limited	7.37%	+1.36pp	2025-12-03

Each holder's own ratio from its most recent large-shareholding report.